Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Boston Medical Center
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02910570CT.gov Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoarthritis, Knee
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Liraglutide (this asset) | Boston Medical Center | Approved | BB · 68 |
| Duloxetine | Orthopaedic Arthroscopy Knee and Shoulder Clinic | P4 | BBB |
| Naproxen | Pfizer | P3 | BB |
| Kenacort | Mayo Clinic | P4 | BB |
| Dextrose Solution | Kastamonu University | P4 | BB |
| Remimazolam | Seoul National University Hospital | P4 | BB |
| Dexmedetomidine | Poznan University of Medical Sciences | P4 | BB |
| Dexasone | Poznan University of Medical Sciences | P4 | BB |
| Triamcinolone Hexacetonide | Kastamonu University | P4 | BB |
+40 more in the Osteoarthritis, Knee cohort
Other indications for Liraglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 84 |
| Type 1 Diabetes Mellitus | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 79 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Liraglutide in Osteoarthritis, Knee. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/liraglutide-osteoarthritis-knee
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →